Jorge E Lascano, MD - Research

Research at a glance

Top areas of exploration

alpha 1-Antitrypsin Deficiency , 9 publications
Pulmonary Disease, Chronic Obstructive , 8 publications
alpha 1-Antitrypsin , 7 publications
Cystic Fibrosis , 4 publications

Research activity

44 publications

376 citations

Why is this important?

Active clinical trials

Serpentine-1

The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency鈥�

Investigator: Jorge E Lascano
Status: Accepting Candidates
Ages: 18 Years - 70 Years
Sexes: All

KB407-02

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Investigator: Jorge E Lascano
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

ELEVAATE OLE

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema

Investigator: Jorge E Lascano
Status: Accepting Candidates
Ages: 18 Years - 80 Years
Sexes: All

My publications

44 publications

2025

Inhaled alpha-1 antitrypsin (AAT) restores lower respiratory tract protease-antiprotease homoeostasis and reduces inflammation in AAT-deficient individuals: a randomised phase 2 study.

ERJ open research

鈥�

2024

Liver Characterization of a Cohort of Alpha-1 Antitrypsin Deficiency Patients with and without Lung Disease.

Journal of clinical and translational hepatology

鈥�

2024

Recombinant Alpha-1 Antitrypsin-Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study.

Chronic obstructive pulmonary diseases (Miami, Fla.)

鈥�

2023

Augmentation Therapy Modulates Systemic Inflammation in Individuals with Alpha-1 Antitrypsin Deficiency and Chronic Obstructive Pulmonary Disease.